Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer

Gynecologic Oncology

Volumn 109, Issue 1, 2008, Pages 39-42

  Black, Destin ^a   Levine, Douglas A ^a   Nicoll, Linda ^a   Chou, Joanne F ^a   Iasonos, Alexia ^a   Brown, Carol L ^a   Sonoda, Yukio ^a   Chi, Dennis S ^a   Leitao, Mario M ^a   Abu Rustum, Nadeem R ^a   Ferguson, Sarah E ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Intraperitoneal catheter; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; PACLITAXEL; PLATINUM;

ALLERGY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CATHETER COMPLICATION; DEHYDRATION; DRUG WITHDRAWAL; HEALTH HAZARD; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOTHERAPY; NAUSEA AND VOMITING; NEUROPATHY; OVARY CANCER; PERITONEAL CATHETER; PRIORITY JOURNAL; WOUND DEHISCENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CATHETERIZATION; CATHETERS, INDWELLING; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 40949110447     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.12.004     Document Type: Article

References (17)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Ozols R.F. Update of the NCCN ovarian cancer practice guidelines. Oncology (Williston Park) 11 (1997) 95-105
3. Ozols R., and Rubin S.C. Epithelial Ovarian Cancer. 4th ed. (2005), Lippincott Williams & Wilkins, Philadelphia
4. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
5. Gadducci A., Carnino F., Chiara S., Brunetti I., Tanganelli L., Romanini A., et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 76 (2000) 157-162
6. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
7. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
8. Yen M.S., Juang C.M., Lai C.R., Chao G.C., Ng H.T., and Yuan C.C. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 72 (2001) 55-60
9. NCI Clinical Announcement, 1/5/06. In: Intraperitoneal chemotherapy for ovarian cancer. ctep.cancer.gov/highlights/clin_annc_010506.pdf.
10. Walker J.L., Armstrong D.K., Huang H.Q., Fowler J., Webster K., Burger R.A., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100 (2006) 27-32
11. Makhija S., Leitao M., Sabbatini P., Bellin N., Almadrones L., Leon L., et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol 81 (2001) 77-81
12. Kirmani S., Braly P.S., McClay E.F., Saltzstein S.L., Plaxe S.C., Kim S., et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54 (1994) 338-344
13. Polyzos A., Tsavaris N., Kosmas C., Giannikos L., Katsikas M., Kalahanis N., et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 56 (1999) 291-296
14. Davidson S.A., Rubin S.C., Markman M., Jones W.B., Hakes T.B., Reichman B., et al. Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol 41 (1991) 101-106
15. Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 90 (2003) 637-643
16. Markman M., and Walker J.L. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24 (2006) 988-994
17. Husain A., Sabbatini P., Spriggs D.R., Fennelly D., Aghajanian C., Barakat R., et al. Phase II trial of intraperitoneal cisplatin and metoxantrone in patients with persistent ovarian cancer. Gynecol Oncol 73 (1999) 96-101